SCHEMBL8502482

SCHEMBL8502482

COc1ccc(C(=O)c2ccccc2)cc1Cn1ncccc1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ PTGS1 P23219 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.42
▸ ACHE P22303 4/20 0.42
▸ BCHE P06276 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ TACR1 P25103 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8504693 0.86 L3MBTL1 (0.38) CYP1A2CYP2C19MEN1KMT2AMAPT
SCHEMBL8505812 0.86 ADRB2 (0.42) HPGDMEN1KMT2AMAPTALDH1A1
SCHEMBL8503177 0.85 POLB (0.38) MEN1KMT2AMAPTALDH1A1THRB
SCHEMBL8504781 0.82 MAPK1 (0.39) HPGDMEN1KMT2AMAPTALDH1A1
SCHEMBL8502094 0.81 MEN1 (0.45) MEN1KMT2APTGDR2MAPTALDH1A1
SCHEMBL21352405 0.78 MEN1 (0.39) HPGDMEN1KMT2AMAPTLMNA
SCHEMBL8526361 0.76 MAPT (0.43) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL8503797 0.75 MAPK1 (0.44) CYP1A2CYP2C19CYP2D6KMT2AMAPT
SCHEMBL8505614 0.74 NLRP3 (0.41) MAPTALDH1A1
SCHEMBL9364036 0.73 CYP1A2 (0.66) HPGDCYP1A2CYP2C19CYP2D6PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5886178-A ADMINISTERING OF A PROSTAGLANDIN G/H SYNTHASE INHIBITOR TO A PATIENT TO TREAT INFLAMMATORY OR AUTOIMMUNE DISEASES SYNTEX (U.S.A.) INC. (US) 1999-03-23 — — US disclosed
Send feedback